Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of diltiazem standard formulation and diltiazem controlled release in patients with stable angina pectoris: a randomized, double-blind, cross-over, multicenter study.
Vliegen HW, van der Wall EE, Kragten JA, Holwerda NJ, Schenkel WM, Muijs van de Moer WM, ten Kate JB, Mulder PG, Bruschke AV. Vliegen HW, et al. Among authors: holwerda nj. J Cardiovasc Pharmacol. 1993 Apr;21(4):552-9. doi: 10.1097/00005344-199304000-00007. J Cardiovasc Pharmacol. 1993. PMID: 7681899 Clinical Trial.
Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
Van Der Vring JA, Daniëls MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, Hendriks MG. Van Der Vring JA, et al. Among authors: holwerda nj. Br J Clin Pharmacol. 1999 May;47(5):493-8. doi: 10.1046/j.1365-2125.1999.00924.x. Br J Clin Pharmacol. 1999. PMID: 10336572 Free PMC article. Clinical Trial.
Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
van der Vring JA, Daniëls MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, Hendriks MG. van der Vring JA, et al. Among authors: holwerda nj. Angiology. 1999 Jun;50(6):447-54. doi: 10.1177/000331979905000602. Angiology. 1999. PMID: 10378820 Clinical Trial.
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators. Newby LK, et al. Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140-6736(14)60417-7. Epub 2014 Jun 12. Lancet. 2014. PMID: 24930728 Clinical Trial.
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators. Homma S, et al. N Engl J Med. 2012 May 17;366(20):1859-69. doi: 10.1056/NEJMoa1202299. Epub 2012 May 2. N Engl J Med. 2012. PMID: 22551105 Free PMC article. Clinical Trial.
30 results